Abstract
Inflammatory lesions of the skin such as erythema, depigmentation and hair loss were observed in C57/BL6(B6) transgenic mice that carried an intact human genomic interleukin-2 gene (gIL-2 transgenic mice). Accumulation of T lymphocytes in the perivascular and periadnexal areas of the dermis was the first change, followed by dermal papillary oedema, which occurred before the development of macroscopic skin lesions. In 3- or 4-week-old transgenic mice with slight erythema and depigmentation of the skin, there was an increase in the number of perivascular lymphocytes accompanied by the diffuse infiltration of neutrophils and monocytes in the damaged skin. These morphological skin changes were not observed in non-transgenic mice, which were bred together with transgenic litter mates. These findings suggest that lymphocyte infiltration of the perivascular space of the skin is a primary event of exogenously introduced human interleukin-2 gene, resulting in secondary cutaneous changes in gIL-2 transgenic mice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Desquenne-Clark L, Kimura H, Silvers WK (1988) The influence of interleukin 2 on the persistence of tolerance. Transplantation 46: 774–775
Farrar JJ, Benjamin WR, Hilfiker ML, Howard M, Farrar WL, Fuller-Farrar J (1982) The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cells and antibody-forming B cell responses. Immunol Rev 63: 129–166
Fullmer MA, Shen JY, Modlin RL, Rea TH (1987) Immunohistological evidence of lymphokine production and lymphocyte activation antigen in tuberculin reactions. Clin Exp Immunol 67: 383–390
Fuse A, Fujita T, Yasumitsu H, Kashima N, Hasegawa K, Taniguchi T (1984) Organization and structure of the mouse interleukin-2 gene. Nucleic Acids Res 12: 9323–9331
Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI (1987) Dermatologic changes associated with interleukin 2 administration. JAMA 258: 1624–1629
Henney CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291: 335–338
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580
Ishida Y, Nishi M, Taguchi O, Inaba K, Minato N, Kawaichi M, Honjo T (1989) Effects of the deregulated expression of human interleukin-2 in transgenic mice. Int Immunol 1: 113–120
Kaplan G, Kiessling R, Teklemariam S, Hancock G, Sheftel G, Job CK, Converse P, Ottenhoff THM, Becx-Bleumink M, Dietz M, Cohn ZA (1989) The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 169: 893–907
Katsuki M, Kimura M, Ohta M, Otani H, Tanaka O, Yamamoto T, Nozawa-Kimura S, Yokoyama M, Nomura T, Habu S (1989) Lymphocyte infiltration into cerebellum in transgenic mice carrying human IL-2 gene. Int Immunol 1: 214–218
Kuziel WA, Takashima A, Bonyhadi M, Bergstresser PR, Allison JP, Tigelaar RE, Tucker PW (1987) Regulation of T-cell receptor γ-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature 328: 263–266
Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117–3124
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764–2772
Mita S, Maeda S, Obaru K, Nishino N, Shimada K, Hirano T, Onoue K, Ogawa T, Ogawa H (1983) Isolation and characterization of a human interleukin 2 gene. Biochem Biophys Res Commun 117: 114–121
Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1008
Nixon-Fulton JL, Bergstresser PR, Tigelaar RE (1986) Thy-1+ epidermal cells proliferate in response to concanavalin A and interleukin 2. J Immunol 136: 2776–2786
Ralfkiaer E, Wantzin GL, Stein H, Thomsen K, Mason DY (1986) T-cell growth factor receptor (Tac-antigen) expression in cutaneous lymphoid infiltrates. J Am Acad Dermatol 15: 628–637
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 313: 1483–1492
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905
Willms-Kretschmer K, Flax MH, Cotran RS (1967) The fine structure of the vascular response in hapten-specific delayed hypersensitivity and contact dermatitis. Lab Invest 17: 334–349
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akiyama, M., Yokoyama, M., Katsuki, M. et al. Lymphocyte infiltration of the skin in transgenic mice carrying the human interleukin-2 gene. Arch Dermatol Res 285, 379–384 (1993). https://doi.org/10.1007/BF00372129
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00372129